Azacitidine (5-Azacytidine)

Name: Azacitidine (5-Azacytidine)
Brand: Selleck Chemicals
SKU: S1782
Rating: 5 (30 reviews)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza

30 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Selleck's Azacitidine (5-Azacytidine) has been cited by 30 publications

Cancer Cell, 2018, 34(5):724-740.e4

PubMed: 30423294 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31382-X

PubMed: 29249359 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Neoplasia, 2020, 22(3):142-153

PubMed: 32062068 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Clin Transl Oncol, 2020, 10.1007/s12094-020-02464-x

PubMed: 32737836 ( click the link to review the publication )

Stem Cell Reports, 2020, 15(2):408-423

PubMed: 32735821 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128571

PubMed: 31437130 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Environ Toxicol, 2019, 10.1002/tox.22873

PubMed: 31724259 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30412053 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 5;37(1):305

PubMed: 30518424 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Int J Mol Sci, 2018, 20(1)

PubMed: 30577584 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1243-1254

PubMed: 28522693 ( click the link to review the publication )
Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Sci Transl Med, 2015, 7(290):290ra89

PubMed: 26041706 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rJe\|AvOS13MDFOwG0>	MmexNVIuPzJiaB?=		MoHabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M2jiTFI3OTN\|MkS2
Jurkat	NXL6bWE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXywMlEuPTBizszN	M2rVV\|EzNTd{IHi=		MlXrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MX:yOlE{OzJ2Nh?=
CA46	MVzGeY5kfGmxbjDBd5NigQ>?	NVvOTVRxOjEEoNM1US=>	Mn;LOFghcA>?		NYjneHdOcW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO\|aX;u	M1e1cFI3OTN\|MkS2
Raji	M{nZdmZ2dmO2aX;uJGF{e2G7	MVyxOeKhyrWP	MWG0PEBp		M3HaNolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?=	M{KyZ\|I3OTN\|MkS2
Jurkat	MkO3SpVv[3Srb36gRZN{[Xl?	MX[zMlXDqML3TR?=	NFH0SZY1QCCq		MULpcoNz\WG\|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25?	MXKyOlE{OzJ2Nh?=
MDA-MB-231	MXHGeY5kfGmxbjDBd5NigQ>?	M3u1VVEwOi53L{Wg{txO	M136WlQ5KGh?		NWDVUYw6\GWlcnXhd4V{KHSqZTDQWHBPOTJiZYjwdoV{e2mxbjDheEB1cGViY3;uZ4VzdnS{YYTpc44hd2ZiNdMg{txOKDR6wrDo	MXiyOVgyPzJ{OR?=
MDA-MB-231	MUnGeY5kfGmxbjDBd5NigQ>?	NH\zbVAyNzJwNT:1JO69VQ>?	M3z4fVQ5KGh?		MmjLbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiRT3jZYRp\XKrbjDtVm5CKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAzNjYEoN88UYZweiB2ONMgbC=>	NILYZ\|AzPThzN{KyPS=>
MDA-MB-231	NYfmcpdMTnWwY4Tpc44hSXO\|YYm=	NWPuXll2OS9{LkWvOUDPxE1?	NFHZUHkzPC92ODDo		M3O2c4lv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=>	M4DuOlI2QDF5MkK5
MCF-7	NUDhXG5VTnWwY4Tpc44hSXO\|YYm=	NV7hXGJlOS9{LkWvOUDPxE1?	MYSyOE81QCCq		NH7T[ZBqdmO{ZXHz[ZMhWEGUUDDjcIVifmGpZdMg	NITN[\|MzPThzN{KyPS=>
MDA-MB-231	NU\1Ro5GTnWwY4Tpc44hSXO\|YYm=	MWOxM\|IvPS93IN88US=>	NVSwSo9WOjRxNEigbC=>		NUHFfZllcW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKG2rUl7BMVEzPCCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2=	MmjBNlU5OTd{Mkm=
A498	MVfGeY5kfGmxbjDBd5NigQ>?	Mki0NVAhyrWP	M2K2PVczKGh?		MUXpcoR2[2W\|IITo[UBCTEGPVGOxPEBo\W6nIHX4dJJme3Orb36=	NGruTFIzPTV4OUC4Oi=>
CaKI-2	NW\TSmF5TnWwY4Tpc44hSXO\|YYm=	M1zyWlExKML3TR?=	MoLLO\|IhcA>?		NXHXZYk3cW6mdXPld{B1cGViQVTBUXRUOThiZ3Xu[UBmgHC{ZYPzbY9v	MVqyOVU3QTB6Nh?=
Ketr-3	NWXzSFNCTnWwY4Tpc44hSXO\|YYm=	NY\jPJRPOTBiwsXN	M13ZdlczKGh?		NIfjNYRqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	MnzxNlU2PjlyOE[=
A253	M{LqW2Z2dmO2aX;uJGF{e2G7	M4\3WlExKML3TR?=	MXSwMVQh\A>?		M4K4U4lv[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsJI9nKHSqZTDNN3LDqGGodHXyJFI1KGh?	M3qwW\|I2PDh3NUO2
A253	MkHxSpVv[3Srb36gRZN{[Xl?	M{TNblExKML3TR?=	NIjHd2I4OiCq		MVnpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{	MluxNlU1QDV3M{[=
A253	M2qxZmZ2dmO2aX;uJGF{e2G7	NHnkelUyOCEEtV2=	NHL4enExNTRiZB?=		M3fZTZJm\HWlZYOgeIhmKDVvbXX0bJlt[3m2b4PpcoUh[2:wdHXueC=>	MUWyOVQ5PTV\|Nh?=
PC3	NVTrNHE2TnWwY4Tpc44hSXO\|YYm=	M4HJNlAvOiEQvF5CpC=>	NYHGRmNEPCCm		NYHkSJg2cW6lcnXhd4V{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gTWdHSlB5LDDTSnJROSCjbnSgV2xEPkFzNTDjc41jcW6nZDD3bZRpKEeVS{GyOi=>	M3PkWVI2PDd5M{Sw
MCF7	MWnGeY5kfGmxbjDBd5NigQ>?	M2naOlAvOyEQvF5CpC=>	M{H5[FQh\A>?		NFvHZVlqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2	M3fZNlI2PDd5M{Sw
PC3	NHHifHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3mWYpqOC5{IN88UeKh	NVv5eZVxPCCm		NEn1Um9l\WO{ZXHz[ZMhfGinIHPlcIwh\3Kxd4ToJJRwKDJyLkOlJINwdWKrbnXkJJdqfGhiR2PLNVI3	MoO3NlU1Pzd\|NEC=
MCF7	MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;GbW94OC5\|IN88UeKh	MWG0JIQ>		M2\yV4Rm[3KnYYPld{B1cGViY3XscEBoem:5dHigNlQvQCViY3;tZolv\WRid3n0bEBIW0tzMk[=	M3vVUlI2PDd5M{Sw
BGC-823	MYnGeY5kfGmxbjDBd5NigQ>?	MUi1xsDPxE1?	MlfkO\|IhcA>?		MWPk[YNz\WG\|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5	NVXHeZVCOjV2N{W3N\|M>
MKN28	NYrjN5lPTnWwY4Tpc44hSXO\|YYm=	NF;USI42yqEQvF2=	NIrTXHY4OiCq		NULXOpp{\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	NXnJU4t4OjV2N{W3N\|M>
SGC-7901	NFjIXJpHfW6ldHnvckBCe3OjeR?=	MXS1xsDPxE1?	MojlO\|IhcA>?		M1fhRoRm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk>	NX:yW\|g5OjV2N{W3N\|M>
MKN45	NXrUdo9[TnWwY4Tpc44hSXO\|YYm=	MlX2OeKh\|ryP	NHzzW2c4OiCq		NF62VmZl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6	NX;YRWdIOjV2N{W3N\|M>
BGC-823	MYjGeY5kfGmxbjDBd5NigQ>?	NFrzVm42yqEQvF2=	NHTSeJg4OiCq		MWjk[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	M130cVI2PDd3N{Oz
MKN28	NHzPPHpHfW6ldHnvckBCe3OjeR?=	NV;KdJk{PcLizszN	Mk\mO\|IhcA>?		MX7k[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	M2XNSlI2PDd3N{Oz
SGC-7901	M1T4TWZ2dmO2aX;uJGF{e2G7	MXi1xsDPxE1?	Mn7ZO\|IhcA>?		M1nt[YRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm=	MXiyOVQ4PTd\|Mx?=
MKN45	NHKwVXdHfW6ldHnvckBCe3OjeR?=	NXvjfW9mPcLizszN	M{XBc\|czKGh?		MWDk[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	M3HafVI2PDd3N{Oz
HREC	M3\OSmZ2dmO2aX;uJGF{e2G7	MlTZOU8yOMLizszN	NYXEOVE3PDhiaB?=		M1fBWIlv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	Ml7RNlU{PTJ5NEe=
HRPE	NUfMN5RKTnWwY4Tpc44hSXO\|YYm=	MWO1M\|ExyqEQvF2=	M4PFNFQ5KGh?		MYHpcoR2[2W\|IGDFSGYhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NVfiN\|Y5OjV\|NUK3OFc>
HREC	MUTGeY5kfGmxbjDBd5NigQ>?	M{HCTVUwOTEEoN88US=>	MWC0PEBp		M3S0d4Rwf25vcnXneYxifGW\|IH;mJHZGT0ZuIFnDRW0uOSBqbn;0JJBzd3SnaX6gcIV3\WxiaX6gTHJRTSClZXzsd{ktKEmOLUJOtkBld3OnLXTldIVv\GWwdHz5	M2\WUVI2OzV{N{S3
HRPE	MoLTSpVv[3Srb36gRZN{[Xl?	MXy1M\|ExyqEQvF2=	NVHzU4NWPDhiaB?=		MYTkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk>	MlruNlU{PTJ5NEe=
MSCs	MlfLSpVv[3Srb36gRZN{[Xl?	NIq2bIcyOCEQvF2=	NW\MNoQ1OjRiaB?=		M{HzbpBzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36=	MnHFNlU{PTF\|OUW=
HL-60	MkjISpVv[3Srb36gRZN{[Xl?	NETsS3M2KM7:TR?=	M{fabVczKGh?	M3nSc2ROW09?	NU[3PFVle2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ\|OEKg[ZhxemW\|c3nvci=>	MofWNlU{OTlyNEm=
MV4-11	M4TmT2Z2dmO2aX;uJGF{e2G7	M3jsT\|Uh\|ryP	NFTYbnk4OiCq	M3;Eb2ROW09?	MVfzbYdvcW[rY3HueIx6KHWycnXneYxifGW\|IGrOSlM5OiCneIDy[ZN{cW:w	NH:wfFQzPTNzOUC0PS=>
A2780	NEjwfHZHfW6ldHnvckBCe3OjeR?=	MX61JOK2VcLi	Ml;1O{Bl		MVXpcoNz\WG\|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt	MoLuNlUzQTl4OUS=
CP70	NIDhWpZHfW6ldHnvckBCe3OjeR?=	NH3qcmg2KML3TdMg	M3H6bVch\A>?		MYTpcoNz\WG\|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt	M3XqTlI2Ojl7Nkm0
A2780	Mn3RSpVv[3Srb36gRZN{[Xl?	MmHPOUDDvU4EoB?=	MYO3JIQ>		NYToWm1Wf2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36=	NGjSSmszPTJ7OU[5OC=>
CP70	NY\DW5VDTnWwY4Tpc44hSXO\|YYm=	M4LDT\|UhyrWPwrC=	NVWyfWJ7PyCm		MUT3[YFs\W6\|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>?	MkL6NlUzQTl4OUS=
OCM3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\0U3AxNjVxMT:yJO69VQ>?	MXW3JIQ>	MUPEUXNQ	M1XGOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M1jkOlI2OTR4OUix
92.1	M1;rW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LUfFAvPS9zL{Kg{txO	M4n3OFch\A>?	MmHiSG1UVw>?	MkO3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MXyyOVE1Pjl6MR?=
OCM1	M164bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\OXlAvPS9zL{Kg{txO	M1nZPFch\A>?	MXHEUXNQ	NH23flhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MUKyOVE1Pjl6MR?=
OMM1	M2L3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjkNE42NzFxMjFOwG0>	NX;ucZY3PyCm	MmXJSG1UVw>?	Mk\ObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MknZNlUyPDZ7OEG=
Mel 285	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWwMlUwOS9{IN88US=>	Ml32O{Bl	NYjCe45KTE2VTx?=	M3Tsb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NXKxO2ZDOjVzNE[5PFE>
Mel 290	NF3hWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX32OlFzOC53L{GvNkDPxE1?	NIKyRlg4KGR?	NHP1PHdFVVOR	MlLHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NH7ldWczPTF2Nkm4NS=>
OCM3	M13KSmZ2dmO2aX;uJGF{e2G7	MnPINE42NzFizszN	M1HkfFQ5KGh?	M4nvTGROW09?	MkD0[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	M4DZZlI2OTR4OUix
92.1	NFrmbZJHfW6ldHnvckBCe3OjeR?=	Ml\PNE42NzFizszN	M1fFbFQ5KGh?	MYfEUXNQ	MnLN[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	MUeyOVE1Pjl6MR?=
OCM1	Ml3sSpVv[3Srb36gRZN{[Xl?	M2Oy[VAvPS9zIN88US=>	Mn76OFghcA>?	NIe5[JpFVVOR	MoLj[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	NXnXT5dkOjVzNE[5PFE>
OMM1	MYDGeY5kfGmxbjDBd5NigQ>?	NEPVUFUxNjVxMTFOwG0>	NF\1OXc1QCCq	NXvTRWRUTE2VTx?=	MU\k[YNz\WG\|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6	M{nzblI2OTR4OUix
Mel 285	NEfISpZHfW6ldHnvckBCe3OjeR?=	M1yzbFAvPS9zIN88US=>	MVq0PEBp	M3zjb2ROW09?	NFrheoRl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7	NVLaNXRxOjVzNE[5PFE>
Mel 290	M3HVfWZ2dmO2aX;uJGF{e2G7	Mn36NE42NzFizszN	MlHROFghcA>?	MUXEUXNQ	M2OzfoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	NXHnOYpkOjVzNE[5PFE>
OCM3	MX7GeY5kfGmxbjDBd5NigQ>?	M3TpfFAvPS9zIN88US=>	M2jmelQ5KGh?	NHO0R2tFVVOR	MUPk[YNz\WG\|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg	MU[yOVE1Pjl6MR?=
Mel 290	MkPpSpVv[3Srb36gRZN{[Xl?	M4nvbFAvPS9zIN88US=>	MVi0PEBp	MWPEUXNQ	Mkfi[IVkemWjc3XzJIlvfmG\|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=>	MVyyOVE1Pjl6MR?=
OMM1	M3vzU2Z2dmO2aX;uJGF{e2G7	MlrSNE42NzFizszN	MV:0PEBp	MonwSG1UVw>?	M1rJXIRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA>	Mm\lNlUyPDZ7OEG=
OCM1	MnXqR4VtdCCYaXHibYxqfHliQYPzZZk>	M1:2V\|AvPS9zIN88US=>	NYe1[I9UPSCm	NUfrUWlETE2VTx?=	M1HUWYRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u	NV3ETXE6OjVzNE[5PFE>
92.1	MnvER4VtdCCYaXHibYxqfHliQYPzZZk>	MmS3NE42NzFizszN	MmHLOUBl	NVf2S5J3TE2VTx?=	MV3k[YNz\WG\|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?=	NIT0So8zPTF2Nkm4NS=>
OCM1	M{fRPWZ2dmO2aX;uJGF{e2G7	M1LRelAvPS9zIN88US=>	MUi0PEBp	MnLISG1UVw>?	NGn6fVhk[XW\|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp	NWi5VnVOOjVzNE[5PFE>
OCM3	NX3tcJdETnWwY4Tpc44hSXO\|YYm=	MlP0NE42NzFizszN	NX7Scot7PDhiaB?=	NELkbpJFVVOR	MYfjZZV{\XNiZ3zvZoFtKESQQTDofZBwdWW2aInsZZRqd25iYYSgUE0yKHKncHXheEBtd2Or	NWP0PJA5OjVzNE[5PFE>
92.1	MmXySpVv[3Srb36gRZN{[Xl?	MmLONE42NzFizszN	NF\rbWc1QCCq	NYfITVNpTE2VTx?=	NIr1c3Zk[XW\|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp	NFzwemwzPTF2Nkm4NS=>
IMR32	MYfGeY5kfGmxbjDBd5NigQ>?	MYCzJO69VQ>?	M1PKSFczKGh?	MYXEUXNQ	M1ezcolv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=>	MkXqNlUyODR6NUC=
IMR5-75	Mn3sSpVv[3Srb36gRZN{[Xl?	NIfLfIY{KM7:TR?=	NYLqS2VtPzJiaB?=	M1ribmROW09?	MmGzbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC\|aXfubYZq[2GwdHz5	MWSyOVExPDh3MB?=
Be(2)-C	Mn;QSpVv[3Srb36gRZN{[Xl?	MXSzJO69VQ>?	M2nYXlczKGh?	MVTEUXNQ	MXLpcoR2[2W\|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	MXWyOVExPDh3MB?=
Bxpc-3	NYnYTJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvYOWRnPS9zMDFOwG0>	NV3MXplrOjRxNEivO\|IhcA>?		M2n4WIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKEK6cHOtN{Bk\WyuczDpckB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{cx?=	MYSyOVA3OTd\|MR?=
Bxpc-3	MoLjRZBweHSxc3nzJGF{e2G7	NHPIdmI2NzFyIN88US=>	M3XWW\|I1NzR6L{eyJIg>		NVLC[5BHcW6mdXPld{BieG:ydH;zbZMhcW5idHnt[U0h[W6mIHPvcoNmem62cnH0bY9vKG2jbn7ldpM>	MVqyOVA3OTd\|MR?=
Bxpc-3	MXnGeY5kfGmxbjDBd5NigQ>?	M3rZXVUwOTBizszN	MX2yOE81QC95MjDo		NXLtWFRq\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo	NUHhZ5hWOjVyNkG3N\|E>
Bxpc-3	NX3hTIRETnWwY4Tpc44hSXO\|YYm=	NU[0XW5vPS9zMDFOwG0>	MXSyOE81QC95MjDo		M1W0c4Rm[3KnYYPld{BkgWOuaX7ENUBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAyOCEQvF2=	NHXGZ3QzPTB4MUezNS=>
Bxpc-3	M4T0S2Z2dmO2aX;uJGF{e2G7	MYW1M\|ExKM7:TR?=	NHL5cI8zPC92OD:3NkBp		M2X2T4Rwf25vcnXneYxifGWVIHOtcZlkKG2UTlGg[ZhxemW\|c3nvckBqdiC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXydy=>	NILHblczPTB4MUezNS=>
HL-60	NVzieJVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXO2bm9ROS5yIN88US=>	NVzY[Wc5PDhiaB?=		MVjzbYdvcW[rY3HueIx6KGmwaHnibZR{KEiOLU[wJINmdGxiZ4Lve5RpyqB?	M3zlS\|I2ODVzMUG5
HL-60	NHHPSmhHfW6ldHnvckBCe3OjeR?=	M13QO\|EvOCEQvF2=	M4H6OlQ5KGh?		MXnpcoNz\WG\|ZYOgdFIyX0GIMT;DTXAyyqCjbnSgZ4F{eGG\|ZT2zJIV5eHKnc4Ppc47DqA>?	MWqyOVA2OTFzOR?=
HL-60	NEXF[mtHfW6ldHnvckBCe3OjeR?=	MUSxMlAh\|ryP	MXS0PEBp		NIDvb2Rl\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	NX;EfWtwOjVyNUGxNVk>
HuTu-80	NHjvUnBHfW6ldHnvckBCe3OjeR?=	NFfkc3gyNzVxMUCg{txO	M1r4blQ5Nzd{IHi=		MYDpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gbJVu[W5iTmDDNWwyKG2UTlGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXHRT\|BCOjR7MESwOlI>
Caco2	NFL2[HlHfW6ldHnvckBCe3OjeR?=	MUexNEDPxE1?	NXnT[INGPDhiaB?=		MlzGbY5kemWjc3XzJG5RSzGOMTDlfJBz\XO\|aX;u	MXyyOFkxPDB4Mh?=
HepG2	NYe0UVNtTnWwY4Tpc44hSXO\|YYm=	MnfiNE0zPSEQvF2=	NH3lZpozPCCq		M4TyNYRm[3KnYYPld{B{fWK2aXzpd4lvN2uneHnuJJR6eGViOTCoVGNUUzlrIIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJk>	MnrmNlQ5PTV4NE[=
HepG2	MmrUSpVv[3Srb36gRZN{[Xl?	NFXNNWgxNTJ3IN88US=>	MVKyOEBp		M{jVZ4lv[3KnYYPld{Btd3diZHXud4l1gSCuaYDvdJJwfGWrbjDy[YNmeHSxcjCoUGRNWiliZ3Xu[UBmgHC{ZYPzbY9vyqB?	MVmyOFg2PTZ2Nh?=
HepG2	MkT3SpVv[3Srb36gRZN{[Xl?	MnnYNVAh\|ryvwrC=	NVPJVWRDOC1{NDDo		NX34UFJD\GWlcnXhd4V{yqCSQ2PLPeKh[W6mwrDIUWdEWsLiZYjwdoV{e2mxbjDhcoQhcW6lcnXhd4V{KEyGTGKg[ZhxemW\|c3nvckBi\nSncjC2JIg>	NV3LXoRvOjR6NUW2OFY>
HepG2	NFnpcVNHfW6ldHnvckBCe3OjeR?=	NWHCW2tIOTBizszt	NFXXRo0zPCCq		NWHLOVhMeHKxbX;0[ZMh[3m2b4PvcIlkKG6ndYTyZYwhdGmyaXSgZYNkfW23bHH0bY9vKGmwZHXw[Y5l\W62bImgc4Yh\XixZ3Xuc5V{KGyrcH;wdo91\Wmwcx?=	NGPRNIYzPDh3NU[0Oi=>
HepG2	NFrudZBHfW6ldHnvckBCe3OjeR?=	Mo\jNVAh\|ryv	NHLWUowzPCCq		M2\KUpBz\X[nboTzJHNTTUKSIIDyc4Nme3Orbne=	MWOyOFg2PTZ2Nh?=
HC45	NXTveo9RTnWwY4Tpc44hSXO\|YYm=	NY\kelQ5PcL3TdMg	NFnEcG41KGR?		M{LPOJJm\HWlZYOgeIhmKG2ndHj5cIF1cW:wIHzleoVteyCxZjDXTWYyNCCSMU[sJGNZS0xzNDygUmtZOuLCk{OsJGNFUDFuIFzBUWEyNCCjbnSgR3RPVkJz	M1\0S\|I1PzZ{OEC5
CNDT2	MorjSpVv[3Srb36gRZN{[Xl?	Mk\YOeK2VcLi	MVu0JIQ>		Mo[wdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF?	MnXINlQ4PjJ6MEm=
CNDT2	NGnWe4NHfW6ldHnvckBCe3OjeR?=	MXy1xtVOyqB?	MVm0JIQ>		M4frUolv[3KnYYPld{Bo\W6nIHX4dJJme3Orb36gc4bDqFeLRkGsJHAyPixiQ1TINUzDqEyDTVGxMOKh[W6mwrDDWG5PSjF?	MnPlNlQ4PjJ6MEm=
T-cells	NEW0PGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVq1M\|IxKM7:TR?=	NUf6OodtOC12ODDo		MoDLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NXnQd\|h2OjR5NUeyPFM>
CD3+ T-cells	MXLGeY5kfGmxbjDBd5NigQ>?	M321TlUwOjBizszN	NXvBcoZzPDhiaB?=		M3rvT5VxemWpdXzheIV{KHBzNTDlfJBz\XO\|aX;u	MV6yOFc2PzJ6Mx?=
CD4+ T-cells	NX\FV5JvTnWwY4Tpc44hSXO\|YYm=	NHPGeFg2NzJyIN88US=>	MkXwOFghcA>?		MUn1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?=	NHLwZ5gzPDd3N{K4Ny=>
CD8+ T-cells	MUDGeY5kfGmxbjDBd5NigQ>?	NFTTbVQ2NzJyIN88US=>	NYLTdIpSPDhiaB?=		MlOweZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36=	MUOyOFc2PzJ6Mx?=
CD3+ T-cells	NXj0[ZM3TnWwY4Tpc44hSXO\|YYm=	MUe1M\|IxKM7:TR?=	MWW0PEBp		M4HJWpVxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKE[RWGCz	NWnVTnZGOjR5NUeyPFM>
CD4+ T-cells	MUDGeY5kfGmxbjDBd5NigQ>?	M4Ltd\|UwOjBizszN	M1jQOlQ5KGh?		MX71dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBHV1iSMx?=	NXPTNG84OjR5NUeyPFM>
CD4+ T-cells	MY\GeY5kfGmxbjDBd5NigQ>?	M1n5OlUwOjBizszN	NGn2PY01QCCq		MXry[YR2[2W\|IGTCSXQyyqCvUl7BJIV5eHKnc4Ppc44>	M33HWVI1PzV5Mkiz
CD4+ T-cells	MUjGeY5kfGmxbjDBd5NigQ>?	M4Dnc\|UwOjBizszN	M1vjTFQ5KGh?		NITDN2R2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\sLiUl;S{tN1yqB?	M{fMT\|I1PzV5Mkiz
CD4+ T-cells	NFnCfJJHfW6ldHnvckBCe3OjeR?=	NF73d3Q2NzJyIN88US=>	MYW0PEBp		MlXObY5pcWKrdIOgcYVud3K7IGStZ4VtdHN?	MW[yOFc2PzJ6Mx?=
CD8+ T-cells	Mlq2SpVv[3Srb36gRZN{[Xl?	NH\Gd3Y2NzJyIN88US=>	Mm\XOFghcA>?		M37pc4lvcGmkaYTzJI1mdW:{eTDUMYNmdGy\|	NWfWWYtIOjR5NUeyPFM>
CD3+ T-cells	M2LuTmZ2dmO2aX;uJGF{e2G7	NXH0R5NyPSEQvF2=	MnXaOFghcA>?		MlXzdoVlfWOnczDsc45oNXSncn2gcYVud3K7IHPlcIwheGinbn;0fZBm	MmG5NlQ4PTd{OEO=
U937	NH2yUYFCeG:ydH;zbZMhSXO\|YYm=	NYTjfJJZOTBizszN	MVO3NkBp		NE\WVWNqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	NEG5eZQzPDZ6MEi2OS=>
HL-60	MnfQRZBweHSxc3nzJGF{e2G7	NYC4[W55OTBizszN	M13zb\|czKGh?		MV7pcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NWTpdWZsOjR4OEC4OlU>
MCF7	NYr2bZhRTnWwY4Tpc44hSXO\|YYm=	M2\mNFUh\|ryP	M4PkRlQ5KGkEoB?=		NYfTNYxV\Gm\|cHzhfZMhe2WuZXP0bZZmKHSxeHnjbZR6KHSxd3Hy[EB{fXOyZX7k[YQhVUOILUegZ4VtdHN?	NGHKRZUzPDZ\|M{O1NC=>
MCF7	NHLsUJBHfW6ldHnvckBCe3OjeR?=	MW[xNEDPxE1?	NUfh[\|BiOjRiaNMg		NGXKdnZqdmS3Y3XzJJRp\SClbHXheoFo\SCxZjDjZZNx[XOnIEegZY5lKFCDUmFCpC=>	MVuyOFY{OzN3MB?=
MCF7	NYHsbGlITnWwY4Tpc44hSXO\|YYm=	NY\Beo9oOOLCk{CuOUDPxE4EoB?=	MWG3JIQ>		NGDB[lhqdmirYnn0d{B1cGViZ4Lve5RpKE2FRj23JJR2dW:{c4Do[ZJmeyCrbjDzeZNx\W6\|aX;uJIN2dHS3cnXzxsA>	NYe4eHptOjR4M{OzOVA>
MCF7	M{HuVWZ2dmO2aX;uJGF{e2G7	NWf4eXhiOC53IN88UeKh	NIm5c\|YyPCCm		NIOxb2tz\WS3Y3XzJJRp\SC\|aYrlJI9nKE2FRj23JINwdG:waXXzJIVu[mWmZHXkJIlvKHOxZoSgZYdieg>?	MWmyOFY{OzN3MB?=
MCF7	MWnGeY5kfGmxbjDBd5NigQ>?	NYHPSHlWOC5yNfMAl\|IxKM7:TR?=	MkfCNUBl		NXTKXmsxemWmdXPld{B1cGViY3zvcoFtKHO3co\peoFtKG:oIF3DSk04KGOnbHzzJIlvKG2xbn;sZZlmeiCldXz0eZJmew>?	NVTwfYdOOjR4M{OzOVA>
T47D	MWHGeY5kfGmxbjDBd5NigQ>?	NIrtfW0xNjVizszN	MmfUOEBl		NXfuOXVucW6qaXLpeJMhfHWvb4LzdIhmemViZn;ycYF1cW:w	NWPOb\|A2OjR4M{OzOVA>
MCF7	NHvodXlHfW6ldHnvckBCe3OjeR?=	NGL6XHIxNjYkgKOxNEDPxE1?	MorDOFghcMLi		MnjobY5pcWKrdIOgeIhmKGejcDDjcI9{fXKnIHnuJJRp\SC5b4Xu[EBp\WGuaX7nJIF{e2G7	NYDLXmtZOjR4M{OzOVA>
MCF7	NFPBeZlHfW6ldHnvckBCe3OjeR?=	M1PTbFAwOTBizszN	NUH3XVBHOjRiaB?=		M3j4WIlvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXA6	M320SlI1PjN\|M{Ww
MDA-MB-231	MkPsSpVv[3Srb36gRZN{[Xl?	NUPzSXRuOC534pETNVAh\|ryP	MoDnN\|YhcA>?		NUnTN3A3cW6qaXLpeJMhfGinIH3p[5JifGmxbh?=	MoHmNlQ3OzN\|NUC=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control. c-PARP / p-H2AX / H2AX; PubMed: 28210112 Lung Cancer (Auckl) AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘	28210112
Immunofluorescence	HMGB1 ; PubMed: 29097772 Sci Rep U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemｾ᎒	29097772
Growth inhibition assay	Cell viability ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖	28210112

In vivo

Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]

Protocol

Cell Research:^[3]	- Collapse Cell lines: Leukemia L1210 cell Concentrations: 0.15 μg/mL Incubation Time: 3 days Method: 5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: BDF1 mice bearing lymphoid leukemia L1210 Dosages: 3 mg/kg Administration: Daily i.p. injection (Only for Reference)

References

[4] Heby O, et al. Cancer Res. 1973, 33(1), 159-165.

- Collapse

Solubility (25°C)

In vitro	DMSO	48 mg/mL warmed (196.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Azacitidine (5-Azacytidine) SDF

Molecular Weight	244.2
Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	5-AzaC,Ladakamycin, AZA,5-Aza
Smiles	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04172844	Recruiting	Drug: Azacitidine\|Drug: Venetoclax\|Drug: Pevonedistat	Acute Myelogenous Leukemia	Ehab L Atallah\|Medical College of Wisconsin	January 13 2020	Phase 1
NCT04214860	Recruiting	Drug: APR-246\|Drug: Venetoclax\|Drug: Azacitidine	Myeloid Malignancy	Aprea Therapeutics	December 13 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?
Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Choose Your Country or Region

By Signaling Pathways

By product type

Azacitidine (5-Azacytidine)